Scientific Session
Systemic lupus erythematosus (SLE)
Victoria Werth, MD
University of Pennsylvania
Wynnewood, PA, United States
Disclosure: Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); AnaptysBio: Consultant (Ongoing); argenx: Consultant (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb (BMS): Consultant (Ongoing); Celgene: Consultant (Terminated, December 31, 2021), Grant/Research Support (Terminated, December 31, 2021); Corbus: Grant/Research Support (Ongoing); CSL Behring: Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing); EMD Serono: Consultant (Ongoing); Galderma: Consultant (Ongoing); Genentech: Consultant (Ongoing), Grant/Research Support (Ongoing); Gilead: Consultant (Ongoing); GlaxoSmithKline (GSK): Consultant (Ongoing); Horizon Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Nektar: Consultant (Ongoing); Novartis: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Consultant (Terminated, December 31, 2021); Regeneron: Consultant (Ongoing), Grant/Research Support (Ongoing); Resolve: Consultant (Terminated, December 31, 2020); Rome Pharmaceuticals: Consultant (Ongoing); Sanofi: Consultant (Ongoing); Syntimmune: Grant/Research Support (Terminated, December 31, 2021); Viela: Consultant (Terminated, December 31, 2021)
Alisa Femia
Disclosure: Disclosure(s): No relevant disclosure to display